RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$7.38
-0.33 (-4.28%)
Open$7.20
Previous Close$7.71
Day High$7.68
Day Low$7.15
52W High$16.19
52W Low$5.46
Volume—
Avg Volume1.28M
Market Cap507.63M
P/E Ratio—
EPS$-3.79
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+150.4% upside
Current
$7.38
$7.38
Target
$18.48
$18.48
$13.35
$18.48 avg
$24.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.32M | 198.05M | 81.92M |
| Net Income | -258,580,903 | -202,755,543 | 13.19M |
| Profit Margin | -113.8% | -108.1% | 16.1% |
| EBITDA | -194,171,263 | -160,709,792 | 28.49M |
| Free Cash Flow | — | — | 20.59M |
| Rev Growth | +14.8% | +14.8% | +8.8% |
| Debt/Equity | 1.82 | 1.82 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |